Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
11/20/201710:00AMPRNUSMylan to Present at Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference
Mylan to Present at Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 20, 2017 HERTFORDSHIRE, England and PITTSBURGH, Nov. 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its president, Rajiv Malik, will present at the Evercore... More...>>
11/13/20179:28AMPRNUSTheravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructiv...
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease Filing Supported by Positive Results from Two Pivotal Phase 3 Efficacy Studies and One 12-Month Phase 3 Safety Study PR Newswire DUBLIN and HERTFORDSHIRE, England and PITTSBURGH... More...>>
11/13/20179:28AMPRNUSTheravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructiv...
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease Filing Supported by Positive Results from Two Pivotal Phase 3 Efficacy Studies and One 12-Month Phase 3 Safety Study PR Newswire DUBLIN and HERTFORDSHIRE, England and PITTSBURGH... More...>>
11/10/20174:45PMPRNUSMylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange (TASE)
Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange (TASE) PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 10, 2017 HERTFORDSHIRE, England and PITTSBURGH, Nov. 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it is voluntarily delisting the company's ordinary shares... More...>>
11/09/20177:30AMPRNUSMylan Launches Generic Clolar® for Injection
Mylan Launches Generic Clolar® for Injection PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2017 HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Clofarabine Injection, 20 mg/20 mL (1 mg/mL) Single-Dose Vials, a generic version... More...>>
11/06/20177:00AMPRNUSMylan Reports Third Quarter 2017 Results and Updates 2017 Guidance
Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2017 HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and nine months ended September 30... More...>>
11/01/20178:30AMPRNUSTheravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at...
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting Presentations Highlight 24-Hour Serial Spirometry Subgroup Findings from Two Replicate Pivotal Phase 3 Studies; Improvements Observed in St. George's Respiratory Questionnaire... More...>>
11/01/20178:30AMPRNUSTheravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at...
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting Presentations Highlight 24-Hour Serial Spirometry Subgroup Findings from Two Replicate Pivotal Phase 3 Studies; Improvements Observed in St. George's Respiratory Questionnaire... More...>>
11/01/20178:00AMGLOBEMomenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)...
CAMBRIDGE, Mass. and HERTFORDSHIRE, United Kingdom and PITTSBURGH, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced that M834, a proposed biosimilar of ORENCIA (abatacept), did not meet its primary pharmacokinetic (PK) endpoints in the... More...>>
11/01/20178:00AMGLOBEMomenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)...
CAMBRIDGE, Mass. and HERTFORDSHIRE, United Kingdom and PITTSBURGH, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced that M834, a proposed biosimilar of ORENCIA (abatacept), did not meet its primary pharmacokinetic (PK) endpoints in the... More...>>
10/31/201712:00PMPRNUSMylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint
Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Oct. 31, 2017 HERTFORDSHIRE, England and PITTSBURGH, Oct. 31, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) provided the following statement in response to the announcement... More...>>
10/27/20176:32PMPRNUSMylan's EpiPen4Schools® Program Surpasses One Million Free Epinephrine Auto-Injector Donations to U.S. Schools
Mylan's EpiPen4Schools® Program Surpasses One Million Free Epinephrine Auto-Injector Donations to U.S. Schools - 2017 marks the five-year anniversary of Mylan's EpiPen4Schools® program. - New data presented at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting showed that more than... More...>>
10/26/20175:23AMPRNUSMylan Wins UK Court Ruling Related to Copaxone® 40 mg/mL Patent
Mylan Wins UK Court Ruling Related to Copaxone® 40 mg/mL Patent PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Oct. 26, 2017 HERTFORDSHIRE, England and PITTSBURGH, Oct. 26, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United Kingdom's High Court of Justice has issued a decision in favor... More...>>
10/25/20174:59AMDJNSanofi Files Patent-Infringement Suit Against Mylan in the U.S.
By Marc Bisbal Arias Sanofi SA (SAN.FR) said late Tuesday that it has brought a patent-infringement suit against Mylan NV (MYL) in a U.S. court over the French company's disposable insulin pen and vial-drug products for diabetes. The pharmaceutical said that the suit it filed in the U.S. District Court for the District... More...>>
10/17/20178:00AMPRNUSMylan to Report Third Quarter 2017 Financial Results on Nov. 6, 2017
Mylan to Report Third Quarter 2017 Financial Results on Nov. 6, 2017 PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Oct. 17, 2017 HERTFORDSHIRE, England and PITTSBURGH, Oct. 17, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Monday, Nov... More...>>
10/16/20176:45PMPRNUSMylan Invalidates Allergan's Patents on Restasis®
Mylan Invalidates Allergan's Patents on Restasis® PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Oct. 16, 2017 HERTFORDSHIRE, England, and PITTSBURGH, Oct. 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United States District Court for the Eastern District of Texas has issued a... More...>>
10/05/20171:23PMPRNUSMylan, in Partnership with Synthon, Receives Marketing Authorization Approval in Europe for First Generic for Copaxone® 40 m...
Mylan, in Partnership with Synthon, Receives Marketing Authorization Approval in Europe for First Generic for Copaxone® 40 mg/mL Mylan Has Exclusive Rights for Glatiramer Acetate in Several Key European Markets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Oct. 5, 2017 HERTFORDSHIRE, England and PITTSBURGH, Oct... More...>>
10/05/20177:30AMPRNUSMylan Launches First AP-rated Generic Avelox® Injection
Mylan Launches First AP-rated Generic Avelox® Injection PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Oct. 5, 2017 HERTFORDSHIRE, England and PITTSBURGH, Oct. 5, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Moxifloxacin Hydrochloride in 0.8% Sodium Chloride Injection, 400... More...>>
10/04/20176:28PMPRNUSMylan Confirms U.S. Launch of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and Generic for Copaxone® 20 mg/mL Once-D...
Mylan Confirms U.S. Launch of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and Generic for Copaxone® 20 mg/mL Once-Daily PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Oct. 4, 2017 HERTFORDSHIRE, England, and PITTSBURGH, Oct. 4, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the... More...>>
10/04/20178:00AMPRNUSMylan Provides Support for U.S. Disaster-Relief Efforts
Mylan Provides Support for U.S. Disaster-Relief Efforts More than 6 Million Doses of Medicine Plus Financial and Other Assistance Provided to Affected Areas PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Oct. 4, 2017 HERTFORDSHIRE, England and PITTSBURGH, Oct. 4, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V:us D:20171121 21:03:33